Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
A worker in a polyvinyl chloride factory with rapidly progressive diffuse cutaneous scleroderma was treated with the humanized monoclonal antibody (Mab) CAMPATH-1H. Treatment was followed by rapid and substantial improvement in skin score, which was maintained during followup without additional ther...
| Những tác giả chính: | , , , , , |
|---|---|
| Định dạng: | Journal article |
| Ngôn ngữ: | English |
| Được phát hành: |
1996
|
| _version_ | 1826281466992001024 |
|---|---|
| author | Isaacs, J Hazleman, B Chakravarty, K Grant, J Hale, G Waldmann, H |
| author_facet | Isaacs, J Hazleman, B Chakravarty, K Grant, J Hale, G Waldmann, H |
| author_sort | Isaacs, J |
| collection | OXFORD |
| description | A worker in a polyvinyl chloride factory with rapidly progressive diffuse cutaneous scleroderma was treated with the humanized monoclonal antibody (Mab) CAMPATH-1H. Treatment was followed by rapid and substantial improvement in skin score, which was maintained during followup without additional therapy. The mode of action of CAMPATH-1H and its relationship to clinical improvement are discussed. |
| first_indexed | 2024-03-07T00:29:14Z |
| format | Journal article |
| id | oxford-uuid:7f32a4fb-fce5-46f5-8f19-06149a9d0e64 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:29:14Z |
| publishDate | 1996 |
| record_format | dspace |
| spelling | oxford-uuid:7f32a4fb-fce5-46f5-8f19-06149a9d0e642022-03-26T21:15:24ZMonoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7f32a4fb-fce5-46f5-8f19-06149a9d0e64EnglishSymplectic Elements at Oxford1996Isaacs, JHazleman, BChakravarty, KGrant, JHale, GWaldmann, HA worker in a polyvinyl chloride factory with rapidly progressive diffuse cutaneous scleroderma was treated with the humanized monoclonal antibody (Mab) CAMPATH-1H. Treatment was followed by rapid and substantial improvement in skin score, which was maintained during followup without additional therapy. The mode of action of CAMPATH-1H and its relationship to clinical improvement are discussed. |
| spellingShingle | Isaacs, J Hazleman, B Chakravarty, K Grant, J Hale, G Waldmann, H Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. |
| title | Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. |
| title_full | Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. |
| title_fullStr | Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. |
| title_full_unstemmed | Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. |
| title_short | Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. |
| title_sort | monoclonal antibody therapy of diffuse cutaneous scleroderma with campath 1h |
| work_keys_str_mv | AT isaacsj monoclonalantibodytherapyofdiffusecutaneoussclerodermawithcampath1h AT hazlemanb monoclonalantibodytherapyofdiffusecutaneoussclerodermawithcampath1h AT chakravartyk monoclonalantibodytherapyofdiffusecutaneoussclerodermawithcampath1h AT grantj monoclonalantibodytherapyofdiffusecutaneoussclerodermawithcampath1h AT haleg monoclonalantibodytherapyofdiffusecutaneoussclerodermawithcampath1h AT waldmannh monoclonalantibodytherapyofdiffusecutaneoussclerodermawithcampath1h |